ose immunotherapeutics covid

 

OSE Immunotherapeutics : fait le point des avancées sur CoVepiT, son vaccin contre la COVID-19, multi-cibles et de protection à long terme 05/11/2020 | 18:01 Envoyer par e-mail : - CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells. Cette étude a … OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company is committed to the fight against COVID-19. Alors que la société biotech française Ose Immunotherapeutics a reçu 5 … Vaccin "pour la vie" contre la Covid-19 : OSE peut enfin lancer un essai clinique. Développé par la biotech OSE Immunotherapeutics, le candidat-vaccin CoVepit "multi-cibles et … Such forward-looking statements are not guarantees of future performance. The main objective of the study was achieved: the identification of T memory immuno-dominant epitopes after infection with COVID-19 and incorporation in the vaccine composition. Connexion membre Connexion client Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, concluded: “We are rapidly advancing our fight against COVID-19, a major public health issue, with a vaccine program especially designed for people at risk, including older adults and immunocompromised populations. OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate. +41 79 367 6254. Ose Immunotherapeutics a mis au point un vaccin contre le COVID-19 qui va entrer prochainement en phase de tests. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile: Vaccine platform The proposed transaction will enable the company to contribute to increasing the overall survival rate and quality of life of patients suffering from cancers and autoimmune diseases, and also encourage the growth and development of European scientific acumen. La biotech française Ose Immunotherapeutics, qui développe entre autres projets un vaccin anti-Covid 19, a obtenu un prêt de 25 millions d'euros … COVID-19 : OSE Immunotherapeutics reçoit l’autorisation pour un essai de Phase 1 avec son vaccin multi-cibles et multi-variants. Cette étude a … The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, comments: “The last year has demonstrated that the COVID-19 is a fast-mutating virus and that vaccination with broader coverage will be needed in the coming months and years, in particular in vulnerable populations. France Description. The European Ombudsman acts as an independent external accountability mechanism of the EIB. La biotech nantaise OSE Immunotherapeutics lève des fonds pour financer son candidat vaccin Covid-19. OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program * Vaccine leverages expertise in peptide selection and optimization and proprietary Memopi® technology to explore a … OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate. La Biotech nantaise ose un vaccin contre les mutations. SOLUTION ? The oral presentation given by Dr. Nicolas Poirier at the virtual 2020 Immunotherapy Congress, titled “CoVepiT: Multiple CD8 T-cell epitopes second-generation SARS-CoV-2 vaccine, long-term lasting tissue-resident memory T cells,” is available on: https://tinyurl.com/yx94gush. Transparency, accountability and access to information, Taxation: avoiding misuse of EIB Group operations, Intermediated loans for SMEs, mid-caps and other priorities, Investments in infrastructure and environmental funds, Guarantees in support of SMEs, mid-caps and other objectives, EU Trade and Competitiveness Programme in Egypt, Jordan, Morocco and Tunisia, Connecting Europe Facility Debt Instrument, EIB in the Mediterranean partner countries, The EIB in the Eastern neighbourhood countries, The EIB in sub-Saharan Africa, the Caribbean and the Pacific, Economic conferences and research networks, Open learning: resources for learners and researchers, Projects to be financed – explanatory notes, Scoreboard - EUROPEAN GROWTH FINANCE FACILITY, Coronavirus pandemic: All about the EIB Group’s response. OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program Clinical Trial Expected to Start in Q1 2021. The Bank's services verified details during the project due diligence. Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, comments: “The last year has demonstrated that the COVID-19 is a fast-mutating virus and that vaccination with broader coverage will be needed in the coming months and years, in particular in vulnerable populations. (AOF) - Ose Immunotherapeutics a finalisé l'étude ex vivo chez l'homme menée avec CoVepiT, son programme de vaccin prophylactique contre la Covid-19. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support The human ex vivo clinical study, named CoVepiT 1, was conducted in 120 convalescent COVID-19 subjects versus unexposed subjects. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. OSE IMMUNOTHERAPEUTICS (EGFF) (COVID-19) Reference: 20190866 Release date: 19 February 2021. Ose Immunotherapeutics annonce, ce lundi, des résultats précliniques positifs concernant son vaccin contre le coronavirus. In addition, this vaccine is designed to anticipate ongoing recurrent virus mutation and evolution, that should reinforce its long-term protective potential. - Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure. Click and follow us on Twitter and LinkedIn. Les premiers résultats précliniques du vaccin contre le Covid-19 sont attendus au début du second semestre. Its team of immunologists is … Location. The proposed transaction will support the emergence of therapeutic solutions for various cancers and autoimmune diseases, some for which current treatments are not satisfactory (such as pancreatic cancer and ulcerative colitis), and others for which there currently are no treatment available (such as Non Small Cell Lung Cancer following immune checkpoint inhibitors failure and Sjögren's syndrome). OSE Immunotherapeutics fait le point des avancées sur CoVepiT, son vaccin contre la COVID-19, multi-cibles et de protection à long terme Boursorama CP • 05/11/2020 à 18:00 Forward-looking statements Ose Immunotherapeutics a finalisé l'étude ex vivo chez l'homme menée avec CoVepiT, son programme de vaccin prophylactique contre la Covid-19. OSE Immunotherapeutics a annoncé la finalisation de l’étude ex vivo chez l’homme menée avec CoVepiT, son programme de vaccin prophylactique contre la COVID-19. Covid-19. This same technology, already in use with Tedopi® in advanced lung cancer, has shown efficacy and good tolerance in this indication and should help accelerate the development process of our COVID-19 vaccine focused on memory CD8 T cell technology.”. Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk. Publié le vendredi 6 novembre 2020. OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company is committed to the fight against COVID-19. +33 607 768 283, U.S. Media: LifeSci Communications Ce vaccin est basé sur la sélection et l’optimisation d’épitopes pour générer une réponse immune des lymphocytes T mémoires sentinelles contre SARS-CoV-2, le virus responsable de la COVID-19. chris@lifesciadvisors.com The project concerns RDI investments in the company's proprietary platform of innovative therapies for immuno-oncology and autoimmune diseases. … In parallel, OSE Immunotherapeutics gave an overview on the development of this multi-target vaccine at the World Immunotherapy Congress, or Festival of Biologics, held virtually November 2-6, 2020. +33 153 198 757, French Media: FP2COM Status: OSE Immunotherapeutics said July 16 it will receive a grant of up to €200,000 ($228,500) from Nantes Metropole, the regional authority for … Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters. OSE Immunotherapeutics développe des … Le groupe français Ose Immunotherapeutics a livré des résultats encourageants pour son candidat vaccin contre la Covid-19. À Nantes, la société de biotechnologie Ose Immunotherapeutics travaille sur un programme baptisé CoVepiT qui vise à mettre au point un vaccin multicible contre le coronavirus. Florence Portejoie OSE IMMUNOTHERAPEUTICS SA. Vaccin "pour la vie" contre la Covid-19 : OSE peut enfin lancer un essai clinique . Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, commented: “The identification of T memory immuno-dominant epitopes, selected for their high potential for immunogenicity, is a major step to move into clinical testing early 2021. Ose Immunotherapeutics, un laboratoire nantais, s’est lancé en mars 2020 dans la course au vaccin contre la covid. • © Ose-Immuno.com Loire-Atlantique Nantes CoVepiT est un vaccin de … OSE Immunotherapeutics However, the promoter's procurement procedures are expected to be in line with the EIB guidelines for private sector projects. La société de biotechnologie OSE Immunotherapeutics attend l'autorisation de … To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. Media-related enquiries can be addressed to the EIB Press Office. Our website uses anonymised cookies to give you the best browser experience and to collect aggregated statistics. Positive preclinical and human ex vivo results in August 2020, clinical trial expected to start end of 2020/early 2021. Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. - Comme beaucoup d'autres, l'entreprise française Ose Immunotherapeutics s'est lancée dans la course au vaccin contre le coronavirus. OSE Immunotherapeutics a annoncé la finalisation de l’étude ex vivo chez l’homme menée avec CoVepiT, son programme de vaccin prophylactique contre la COVID-19. OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company is committed to the fight against COVID-19. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Covid-19. Le groupe français Ose Immunotherapeutics a livré des résultats encourageants pour son candidat vaccin contre la Covid-19. These results from both preclinical and human ex vivo studies as well as the expected emergence of new SARS-CoV-2 variants build a strong basis for supporting the development of CoVepiT as a novel and differentiated COVID-19 vaccine designed against multiple coronavirus targets with vaccinal technology known to induce long-lasting memory T lymphocytes. NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announces successful completion of its human ex vivo study with CoVepiT, a prophylactic vaccine based on optimized epitopes selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2, the virus that causes COVID-19. The company's pipeline includes an immunotherapy that is in Phase III clinical stage for the treatment of lung cancer, as well as in Phase II clinical trial to pancreatic cancer, a humanised monoclonal antibody that is in pre-clinical stage for the treatment of various cancers, a humanised monoclonal antibody that is in Phase I clinical trial for the treatment of inflammatory autoimmune diseases and a prophylactic vaccine against SARS-CoV-2, for which the clinical phase start is expected in Q1-2021. Please also visit our Media information section. In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in monotherapy and in combination with checkpoint inhibitor Opdivo®. The project concerns RDI investments in the company's proprietary platform of innovative therapies for immuno-oncology and autoimmune diseases. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes). We warmly thank all the subjects included and the clinical teams led by Dr Didier Debieuvre, of the Hospital Center Emile Müller of Mulhouse, and Dr Valérie Heyer, of the Marine Firefighters of Marseille, for their participation in our clinical study and commitment to the COVID-19 vaccine development program. They do not constitute historical facts. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. darren@lifescicomms.com Immuno-oncology platform - OSE-127 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; two independent Phase 2 planned in ulcerative colitis (OSE sponsor) and in Sjögren’s syndrome (Servier sponsor) to start in Q4 2020. OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate. OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT PRESS RELEASE GlobeNewswire Aug. 17, 2020, 07:30 AM +1 646 627 8387, U.S. and European Investors À Nantes, Ose Immunotherapeutics développe un vaccin contre la covid-19. OSE Immunotherapeutics travaille à un vaccin contre le Covid-19. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Update Provided in an Oral Presentation at the Annual World Immunotherapy Congress (2-6 November 2020). Scientists warn of new SARS-CoV-2 variants spreading rapidly across Europe and bearing mutation in some key targets of the virus, in particular the Spike protein and Nucleoprotein. Thank you for subscribing to the European Investment Bank’s monthly newsletter. Its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. Location. We are also very pleased to be the first company to present a second-generation COVID-19 memory T cell vaccine with potential for protecting future endemic pan-coronaviruses at a scientific congress.”, Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, concluded: “Using expertise and knowledge gained from our Memopi® epitope vaccinal technology allowed us to quickly develop a COVID-19 vaccine based on peptides, as part of our T cell-based vaccine platform. This is the first presentation on a second-generation memory T cell COVID-19 vaccine at a scientific congress. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy. Ose Immunotherapeutics annonce le lancement un programme de vaccin pouvant prévenir l'apparition, la propagation ou l'aggravation du Covid-19. This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. OSE Immunotherapeutics : feu vert pour l'essai anti-Covid Connectez-vous pour conserver cet article et le lire plus tard. Ose Immunotherapeutics veut vendre son vaccin Covid-19 en 2022, mais ce “ne sera pas trop tard”. The promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending 2011/92/EU. Avec son super vaccin, OSE Immunotherapeutics espère nous protéger à vie de la Covid-19. Pour ce faire, son produit cible onze protéines du virus au lieu de la seule protéine Spike.